BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ in Preclinical Cancer Models
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line modelsImmune cells activated by Bria-OTS+ exhibit serial killing activity across multiple rounds of tumor cell challenge briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (T...